Medicine and application thereof in preparation of medicine for preventing or treating osteoporosis

By extracting the combined use of norpoldine and human amniotic mesenchymal stem cells from traditional Chinese medicine resources, it is prepared into drugs for preventing and treating osteoporosis, which solves the problem that existing therapeutic strategies cannot effectively promote bone formation and increase bone mass. Problem, the significant improvement of osteoporosis effect in mouse models was achieved, and safety and excellent market application prospects were shown.

CN118924753APending Publication Date: 2024-11-12AFFILIATED HOSPITAL OF ZUNYI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411079007.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing treatment strategies for osteoporosis cannot effectively promote bone formation and increase bone mass, and there are safety problems and poor patient compliance. Finding new drugs and treatment methods has become a hot topic in research.

Method used

Extract norprolitsine from traditional Chinese medicine resources as the main active ingredient, combined with human amniotic mesenchymal stem cells, and prepare it into drugs to prevent or treat osteoporosis, including oral and injectable dosage forms, through intraperitoneal injection or tail Intravenous infusion is performed for intervention.

Benefits of technology

In the osteoporosis model of female ICR mice, the combined use of norboldine and human amniotic mesenchymal stem cells significantly increases serum estrogen levels, increases osteocalcin and roitin, reduces bone resorption markers, and promotes bone smallness Beam formation and increase bone density are better than use alone and are non-toxic to major organs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924753A_ABST
    Figure CN118924753A_ABST
Patent Text Reader

Abstract

The invention discloses a medicine in the technical field of medicines, the medicine has a very good effect on preventing or treating osteoporosis by singly using norbodine or combining norbodine with human amniotic mesenchymal stem cells (hAMSCs), can improve the serum estrogen level to a certain extent, can increase the levels of osteocalcin OCN, I-type procollagen amino terminal peptide (PINP) and osteoprotegerin (OPG) in serum, and can be used for treating osteoporosis. According to the invention, the level of tartrate-resistant hydrochloric acid phosphatase (TRAP), type I collagen C-terminal peptide (CTX-1), nuclear factor kappa B receptor activating factor ligand (RANKL), inflammatory factors TNF-alpha and IL-6 in serum is reduced, the formation of bone trabecula is promoted, bone microstructure parameters such as bone mineral density (BMD), bone trabecula number (Tb.N) and bone volume fraction (BV / TV) are increased, and the separation degree Tb.Sp of the bone trabecula is reduced, so that the bone trabecula can be effectively inhibited. Therefore, the effects of promoting bone formation, inhibiting bone resorption and improving osteoporosis of mice are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and particularly relates to a medicine and application thereof in preparing a medicine for preventing or treating osteoporosis. Background Art

[0002] Osteoporosis (OP) is a common systemic bone disease characterized by decreased bone density accompanied by microstructural destruction, increased bone fragility and increased risk of fractures, which leads to increased risk of disability and mortality, especially for the elderly and postmenopausal women (Jia Mingjie et al., Research Progress of Plant Active Ingredients in Anti-Osteoporosis [J], Food Industry Science and Technology, 2022, 43(16): 400-412). According to global health big data analysis, among people over 50 years old, about 20% of men have a chance of suffering from osteoporotic fractures, while the prevalence rate in women is as high as 30% (Dembitsky VM, Gloriozova TA, Poroikov VV. Pharmacological profile of natural and synthetic compounds with rigid adamantane-based scaffolds as potential agents for the treatment of neurodegenerative diseases [J]. Biochem Bioph Res Co, 2020, 529(4): 1225-1241). my country is a country with a high incidence of osteoporosis. With the acceleration of the aging of the population, the effective prevention and treatment of osteoporosis has become one of the severe challenges facing my country's social and public health security.

[0003] The pathogenesis of OP is very complex and has not yet been fully elucidated. Studies have shown that it is closely related to multiple factors such as endocrine disorders, calcium malabsorption, nutrition, genetics, immunity, and aging (Jakob F, et al. Regulation of bonemetabolism in osteoporosis: novel drugs for osteoporosis in development [J]. Unfallchirurg, 2015, 118: 925-932; Del Puente A, et al. Physiopathology of osteoporosis: from risk factors analysis to treatment [J]. J. Biol. Regul. Homeost. 2015, 29: 527-531). Clinically, OP is divided into secondary and primary categories. Secondary OP refers to osteoporosis caused by any factor that can affect bone metabolism (such as disease or drug); primary OP mainly includes specific OP, elderly OP and postmenopausal OP (Liu Guangchen et al., Research Progress on the Effect and Mechanism of Chinese Herbal Polysaccharides in Preventing and Treating Osteoporosis [J], Chinese Herbal Medicine, 2022, 53(12): 3831-3841). According to statistics, the number of female OP patients in my country is significantly higher than that in Europe and the United States. OP is common in postmenopausal women and is attributed to a sharp drop in estrogen levels in the body, which leads to bone absorption intensity being greater than bone formation intensity. Abnormal bone metabolism can cause a large amount of bone loss, thereby causing postmenopausal osteoporosis (PMOP) (Miyauchi, Y. et al. HIF1alpha is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis[J]. Proc. Natl. Acad. Sci. USA 2013, 110(41): 16568–16573; Zhu D, et al. Extragonadal effects of follicle-stimulating hormone on osteoporosis and cardiovascular disease in women during menopausal transition[J]. Trends Endocrinol Metab. 2018, 29(8): 571-580).Currently, the treatment strategies for PMOP include basic therapy and drug therapy. Basic therapy mainly involves adjusting diet and lifestyle, supplementing calcium and vitamin D, and preventing falls; drug therapy mainly includes bone formation promoters (such as parathyroid hormone and its analogs, active vitamin D and its analogs, etc.), bone resorption inhibitors (such as estrogens and bisphosphonates) and dual-action mechanism drugs (such as romozumab) (Liu Xiaopei et al., Meta-analysis of Yougui Pills combined with Western medicine for the treatment of osteoporosis [J], Chinese Journal of Osteoporosis, 2021, 27(6): 781-787). However, the above treatment strategies cannot effectively promote bone formation, increase bone mass and bone density, and can only alleviate PMOP, but cannot cure it. In addition, long-term use of such drugs also has safety issues such as increased blood pressure, gastrointestinal discomfort, hypercalcemia, osteonecrosis, and endometrial carcinoma, as well as limitations such as high price and poor patient compliance (XuHH, et al. Tea polysaccharide inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells and ameliorates ovariectomy-induced osteoporosis in rats [J]. Biomed Pharmacother, 2018, 102: 539-548; Stapleton M, et al. Development of bone targeting drugs [J]. Int J Mol Sci, 2017, 18 (7): 1345). Therefore, finding new drugs and treatments for the prevention and treatment of PMOP has become a research hotspot in the current biomedical field. my country has rich traditional Chinese herbal medicine resources and a broad clinical application base. Finding natural active compounds that can improve bone metabolism and combining them with regenerative medicine centered on stem cell transplantation will become a shortcut and one of the important ways to develop new drugs and treat PMOP. Summary of the invention

[0004] The present invention aims to provide an active ingredient found from traditional Chinese medicine resources for use in preparing a medicine for preventing or treating osteoporosis.

[0005] The first aspect of the present invention is to provide a medicament containing norboldine.

[0006] Furthermore, the medicine also contains human amniotic mesenchymal stem cells.

[0007] Furthermore, the drug is prepared with norboldine as the main active ingredient, and is added with pharmaceutically acceptable carriers and / or excipients to form a pharmaceutically acceptable dosage form, including oral dosage forms and injection dosage forms, wherein the oral dosage form is such as granules, solutions, pills, pastes or tablets.

[0008] The above-mentioned laurolitsine (LAU), also known as neo-oligospermum officinale, belongs to the quinoline alkaloid compound and is one of the main active ingredients of the traditional Chinese herbal medicine Linderae umbellatae. The structure of laurolitsine is shown below:

[0009]

[0010] The second aspect of the present invention is to use the above-mentioned medicine in the preparation of medicine for preventing or treating osteoporosis.

[0011] Furthermore, the osteoporosis includes specific osteoporosis, senile osteoporosis and postmenopausal osteoporosis.

[0012] The third aspect of the present invention is to use the above-mentioned drug in the preparation of a drug for increasing trabecular bone and / or bone density.

[0013] The fourth aspect of the present invention is to use the above-mentioned drug in the preparation of a drug for inhibiting bone resorption and / or promoting bone formation.

[0014] The applicant conducted an in-depth study on the pharmacology of LAU and found that the use of norboldine alone or in combination with human amniotic mesenchymal stem cells hAMSCs has a very good effect on the prevention or treatment of osteoporosis. An osteoporosis model was established by bilateral ovariectomy in 8-week-old female ICR mice. It was found that intraperitoneal injection of norboldine alone or combined with tail vein infusion of hAMSCs, after continuous intervention for 8 weeks, can increase serum estrogen levels to a certain extent, increase serum osteocalcin OCN, type I procollagen amino-terminal peptide (PINP) and bone protection The results showed that the combination of norboldine and hAMSCs increased the level of OPG, reduced the levels of tartrate-resistant acid phosphatase (TRAP), type I collagen C-terminal peptide (CTX-1), nuclear factor κB receptor activator ligand (RANKL), inflammatory factors TNF-α and IL-6 in serum, promoted the formation of trabeculae, increased bone microstructure parameters such as bone mineral density (BMD), trabecular number (Tb.N) and bone volume fraction (BV / TV), and reduced the trabecular separation Tb.Sp, thereby promoting bone formation and inhibiting bone resorption, and improving osteoporosis in mice. The combined intervention group of norboldine and hAMSCs was better than that of the group using it alone, and no toxicity was shown to major organs. The use of norboldine alone or in combination with hAMSCs to prepare drugs for the prevention and / or treatment of osteoporosis, especially postmenopausal osteoporosis, has broad market application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The chemical structure of norboldine (LAU).

[0016] Figure 2 To screen the dosage and ratio of LAU and hAMSCs.

[0017] Figure 3 HE staining was used to analyze the histopathological changes of the main organs of the mice after 8 weeks of LAU and hAMSCs treatment of osteoporosis mouse model (bar=100 μm).

[0018] Figure 4 Micro-CT analysis of femoral bone mass and bone microstructure changes after 8 weeks of LAU and hAMSCs treatment of osteoporosis mouse model: (A) Micro-CT image of femur; (B) changes in bone density; (C) changes in the number of trabeculae; (D) changes in the average thickness of trabeculae; (E) changes in the separation of trabeculae; (F) changes in bone volume fraction; (G) Micro-CT image of femoral cortical bone; (H) changes in cortical bone thickness; (I) changes in cortical bone area.

[0019] Figure 5 After 8 weeks of LAU and hAMSCs treatment of osteoporosis mouse model, ELISA was used to analyze the changes in serum estrogen, bone resorption and bone formation markers, and inflammatory factors: (A) changes in estrogen; (B) changes in bone formation marker osteocalcin; (C) changes in bone formation marker type I procollagen amino-terminal peptide; (D) changes in bone formation marker osteoprotegerin; (E) changes in bone resorption marker tartrate-resistant acid phosphatase; (F) changes in bone resorption marker type I collagen C-terminal peptide; (G) changes in bone resorption marker nuclear factor κB receptor activator ligand; (H) changes in inflammatory factor TNF-α; (I) changes in inflammatory factor IL-6.

[0020] As shown in the figure: SHAM is the sham operation group; OVX is the model group; LAU is the norboldine intervention group; hAMSCs is the human amniotic mesenchymal stem cell intervention group; hAMSCs+LAU is the norboldine and human amniotic mesenchymal stem cell combined intervention group; E2 is the positive drug estradiol intervention group; OCN is osteocalcin; PINP is type I procollagen amino-terminal peptide; OPG is osteoprotegerin; TRAP is tartrate-resistant acid phosphatase; CTX-1 is type I collagen C-terminal peptide; RANKL is nuclear factor κB receptor activator ligand; BMD is bone mineral density; Tb.N is the number of trabeculae; BV / TV is the bone volume fraction; Tb.Sp is the trabecular separation; Tb.Th is the average trabecular thickness; Ct.Th is the cortical bone thickness; Ct.Ar is the cortical bone area. n=6, #P<0.05, ##P<0.01 vs SHAM group; *P<0.05, **P<0.01 vs OVX group. DETAILED DESCRIPTION

[0021] 1. Preparation of norboldine (LAU) solution

[0022] Accurately weigh a certain amount of LAU powder (CAS No. 5890-18-6), use injection-grade olive oil (CAS No. 8001-25-0) to prepare a certain concentration of mother solution, use EP tubes and seal them to store in the dark for later use. When intervening in vivo, dilute it with injection-grade olive oil to the required working concentration and then inject it intraperitoneally. Similarly, accurately weigh a certain amount of estradiol (17β-estradiol, E2, CAS No. 50-28-2) as a positive control drug, and the olive oil dissolution process is the same as LAU.

[0023] The chemical structure of the norboldine is as follows Figure 1 shown.

[0024] 2. Isolation and culture of human amniotic mesenchymal stem cells (hAMSCs)

[0025] The isolation and culture of hAMSCs has passed the ethical review of the Medical Ethics Committee of Zunyi Medical University (Zunyi Lunshen (2023) No. 1-130). The sampling vessel was sterilized in advance by high pressure and placed in an oven to dry. The healthy placenta obtained by full-term cesarean section was placed in a clean surgical tray, and the bloody placenta was rinsed with D-PBS containing 1% penicillin and streptomycin. The amniotic membrane on the surface of the placenta was carefully peeled off with high-pressure sterilized surgical scissors and tweezers, and placed in a container filled with D-PBS. After returning to the laboratory, the amniotic membrane was immediately placed in a UV-sterilized clean bench. The amniotic membrane was cut into pieces of about 1cm-3cm with sterilized scissors and placed in a 50mL centrifuge tube. 0.5% trypsin digestion solution containing 0.02% EDTA-2Na was added in an amount twice the volume of the amniotic membrane. The mouth of the centrifuge tube was sealed with a sealing film and placed in a 37°C shaker for 90 minutes of shaking digestion. The amniotic membrane was filtered through a 300-mesh stainless steel filter. The filtered amniotic membrane was washed several times with D-PBS and placed in a 50mL centrifuge tube again. A volume of 0.5mg / mL DNase I containing 0.05mg / mL DNase I was added. Type II collagenase, after mixing, seal the mouth of the centrifuge tube with a sealing film, place it in a 37°C shaker for shaking digestion until the amniotic tissue in the centrifuge tube disappears and becomes transparent, which takes about 60 minutes, and filter it again with a 300-mesh stainless steel filter. Put the filtered liquid into a new 50mL centrifuge tube, centrifuge it at 1500rpm for 10 minutes, discard the supernatant, add LG-DMEM / F12 complete medium to resuspend the precipitate, and plant it in a T75 cell culture bottle, and culture it in a CO2 incubator at 37°C, 5% CO2, and saturated humidity, which is the primary hAMSCs, marked as P0. Observe the cell growth every day, discard the culture medium when it turns yellow, wash it repeatedly with D-PBS, and add 10mL complete medium LD-DMEM / F12 to continue culturing. When the fusion degree of hAMSCs adherent cells reaches more than 80%, discard the medium, wash with D-PBS 2-3 times, digest with 0.125% trypsin containing 0.02% EDTA-2Na in a 37℃ CO2 incubator for 2 minutes, tap the culture bottle and observe whether the adherent cells fall off under a microscope, add an equal volume of LG-DMEM / F12 complete medium to terminate digestion, transfer to a 50mL centrifuge tube, centrifuge at 1200rpm for 5 minutes, discard the supernatant, resuspend with an appropriate amount of LG-DMEM / F12 complete medium, and inoculate in a new T75 cell culture bottle, which is the P1 generation cell. Observe the cell growth status regularly for passage, and take the P3 generation cells with good growth status for subsequent experiments.

[0026] LAU alone or in combination with hAMSCs for the prevention and / or treatment of osteoporosis

[0027] 1. Establishment of Bilateral Ovariectomy (OVX) Model

[0028] Animal husbandry and experimental procedures have passed the ethical review of experimental animal welfare of Zunyi Medical University (ZMU21-2302-099). After one week of adaptive feeding, 8-week-old female ICR mice (provided by Changsha Tianqin Biotechnology Co., Ltd., license number SCXK (Xiang) 2019-0013) were anesthetized by a single intraperitoneal injection of 1% sodium pentobarbital. The hair was shaved 1 cm below the ribs and 2 cm beside the spine with a razor, disinfected with iodine, and a 1cm-2cm incision was made with a scalpel. The abdominal cavity was opened to find the pink tissue wrapped in white fat tissue. The granular protrusions on the surface were ovarian tissue, which was cut with scissors (the normal group removed ovarian-sized fat tissue). The fallopian tubes were ligated, the abdominal cavity was closed, and the wound was sutured. Recovery for one week.

[0029] 2. Exploration of dosage and ratio of LAU and hAMSCs

[0030] First, the dosage and ratio of LAU and hAMSCs were preliminarily explored by analyzing the changes in serum estrogen levels in bilaterally ovariectomized (castration model) mice.

[0031] LAU was divided into low (LAU-L, 4 mg / kg), medium (LAU-M, 20 mg / kg) and high-dose (LAU-H, 100 mg / kg) groups, and intraperitoneal injections were performed every other day.

[0032] hAMSCs were also set at low levels (hAMSCs-L, 2.0×10 5 ), medium (hAMSCs-M, 2.0×10 6 ) and high dose (hAMSCs-H, 2.0×10 7 ) Transplantation group, the transplantation was performed by tail vein infusion once every two weeks.

[0033] A two-factor three-level orthogonal experiment was designed, and the mice were divided into 11 groups, with 4 mice in each group, namely sham operation group (SHAM), model group (OVX), LAU-L+hAMSCs-L group, LAU-L+hAMSCs-M group, LAU-L+hAMSCs-H group, LAU-M+hAMSCs-L group, LAU-M+hAMSCs-M group, LAU-M+hAMSCs-H group, LAU-H+hAMSCs-L group, LAU-H+hAMSCs-M group, and LAU-H+hAMSCs-H group. The detailed treatments are as follows:

[0034] In the SHAM group, bilateral sham ovariectomy and normal feeding were performed; in the OVX group, bilateral ovariectomy and normal feeding were performed; in the 9 drug intervention groups, bilateral ovariectomy was performed, LAU was dissolved in olive oil and injected intraperitoneally every other day at low, medium or high doses, and hAMSCs cells were transplanted through the tail vein at low, medium or high doses once every two weeks, for a total of 4 times.

[0035] 3. The optimal dosage and ratio of LAU and hAMSCs for improving osteoporosis symptoms in mice

[0036] After screening out the optimal dosage and ratio of LAU and hAMSCs to regulate the serum estrogen level in mice, the effect mechanism of improving osteoporosis in mice was further systematically evaluated. The mice were divided into 6 groups, with 10 mice in each group, namely sham operation group (SHAM), model group (OVX), LAU treatment group (LAU), hAMSCs treatment group (hAMSCs), LAU+hAMSCs combined treatment group (hAMSCs+LAU), and estradiol 17β-estradiol treatment group (E2 group, E2). The detailed treatments are as follows: (a) SHAM group, bilateral sham ovariectomy and normal feeding; (b) OVX group, bilateral ovariectomy and normal feeding; (c) LAU group, bilateral ovariectomy, olive oil-dissolved LAU, intraperitoneal injection every other day at 20 mg / kg; (d) hAMSCs group, bilateral ovariectomy, tail vein infusion of transplanted cells once every two weeks, 2.0×10 6 hAMSCs cells / time, 4 times in total; (e) hAMSCs+LAU group, ovaries were removed bilaterally, LAU was dissolved in olive oil and injected intraperitoneally at 20 mg / kg every other day, and transplanted cells were infused into the tail vein once every two weeks, 2.0×10 6 hAMSCs cells / time, for a total of 4 times; (f) E2 group, bilateral ovaries were removed, E2 dissolved in olive oil was injected intraperitoneally at 10 μg / kg every other day.

[0037] Mouse sampling: Each group terminated treatment after 8 weeks of treatment. After fasting for 8 hours, the mice were anesthetized to coma with 1% sodium pentobarbital, and the eyeballs were removed. Blood was collected in a marked 1.5 mL EP tube, and the tube was allowed to stand for 15 minutes at 3000 rpm after coagulation. The supernatant was divided into sterilized EP tubes and stored at -20°C for later use. The mice after blood collection were killed by cervical dislocation. The heart, liver, spleen and kidney were peeled off and placed in a 5 mL EP tube, which was stored at -80°C for later use. After peeling off the muscle tissue around the femur, it was wrapped with gauze soaked in saline and placed in a -80°C refrigerator.

[0038] The main organ tissues of mice in each group were fixed with 4% paraformaldehyde for 48 hours, and then paraffin sections were cut and routine HE staining was performed for observation; the distal end of the left femur of mice in each group was CT scanned (SkyScan 1176micro-CT, Bruker, Belgium), which was commissioned to Chengdu Lilai Biotechnology Co., Ltd.; the serum was taken out from the -80℃ refrigerator, and after it was completely dissolved, it was diluted to a certain concentration according to the instructions of the ELISA detection kit (Shanghai Jianglai Biotechnology Co., Ltd.) and the expression of related cytokines in the serum was detected.

[0039] 3. Results Analysis

[0040] (1) Determination of the optimal dosage and ratio of LAU and hAMSCs

[0041] In mice with bilateral ovarian removal, the secretion level of estrogen (E2) decreases, its inhibition on osteoclasts weakens, osteoclast function becomes more active, and the compensatory function of osteoblasts increases, but the overall trend is that bone absorption is greater than bone formation, and the bones are in a high turnover state. The osteoporosis caused by this model is similar to the bone loss of human women after menopause.

[0042] We first constructed an osteoporosis model in bilaterally ovariectomized mice (castration model), and set up intraperitoneal administration groups of LAU low (LAU-L, 4 mg / kg), medium (LAU-M, 20 mg / kg), and high (LAU-H, 100 mg / kg) and hAMSCs low (hAMSCs-L, 2.0×10 5 ), medium (hAMSCs-M, 2.0×10 6 ), high dose (hAMSCs-H, 2.0×10 7 ) tail vein transplantation infusion group, and two-factor three-level orthogonal test was carried out in pairs to investigate the regulatory effect of different combinations on the serum E2 level of osteoporotic mice, so as to determine the optimal dosage and ratio of LAU and hAMSCs.

[0043] The experimental results are as follows Figure 2As shown in the figure, the serum E2 content in the SHAM group was 764.26 pg / mL, while the serum E2 content in the OVX group decreased to 260.37 pg / mL (P<0.01), indicating that the estrogen secretion level of mice was significantly reduced after ovariectomy, and the model was successfully established. Compared with the OVX group, after 8 weeks of combined intervention of LAU-L with hAMSCs-L, hAMSCs-M and hAMSCs-H in OVX mice, the serum E2 content was 279.52 pg / mL (P>0.05), 349.90 pg / mL (P<0.05) and 349.77 pg / mL (P<0.01), respectively, indicating that the combination of LAU-L with hAMSCs-M and hAMSCs-H can upregulate the serum estrogen level of OVX mice, and the upregulation multiple is about 1.35 times.

[0044] After 8 weeks of combined intervention of LAU-M with hAMSCs-L, hAMSCs-M and hAMSCs-H in OVX mice, the effect was significantly stronger than that of the LAU-L combination group. Among them, the combination of LAU-M and hAMSCs-M had the best effect, with serum E2 content of 683.60 pg / mL (P<0.01), which was 2.63 times that of the OVX group.

[0045] When the LAU dose was further increased and LAU-H was used in combination with hAMSCs-L, hAMSCs-M and hAMSCs-H to intervene in OVX mice for 8 weeks, the serum E2 levels were 233.33 pg / mL (P>0.05), 267.53 pg / mL (P>0.05) and 218.45 pg / mL (P>0.05), respectively, and none of them showed the effect of increasing serum E2 levels.

[0046] The above results suggest that LAU has the effect of upregulating the serum E2 content of mice at a dose of 4 mg / kg, and its effect increases with the increase of concentration, but it may be due to its toxicity at high doses. The dose of 100 mg / kg did not show the effect of upregulating the serum E2 content; hAMSCs at 2.0×10 5 The transplantation dose had no significant effect on the serum E2 content of mice. 6 and 2.0×10 7 The transplantation dose can upregulate the serum E2 content of mice, but the hAMSCs-M group has a stronger effect. Therefore, the optimal dose and ratio of the two were finally determined as follows: LAU intraperitoneal injection of 20 mg / kg each time and hAMSCs tail vein transplantation of 2.0×10 6 Subsequent experiments further used this dosage and ratio system to study its improvement effect and possible mechanism on the symptoms related to osteoporosis in mice.

[0047] (2) Effects of LAU and hAMSCs intervention on pathological changes of major organs in osteoporotic mice

[0048] The mouse osteoporosis model was established by bilateral ovariectomy (castration model). The mice in each group were sacrificed after 8 weeks of intervention according to the experimental method. The heart, liver, spleen and kidney were obtained for HE staining and pathological observation. The experimental results are shown in Figure 3 As shown. The liver tissue structure of the SHAM group was clear and the hepatocytes were neatly arranged, while the staining of the OVX group, LAU group, hAMSCs group, hAMSCs+LAU group and E2 group was similar to that of the SHAM group, with no obvious structural damage and inflammatory cell infiltration. Similar to the HE staining results of liver tissue, HE staining of kidney tissue of mice in each group showed that the cell structure in the renal cortex and medulla region was clearly visible and neatly arranged, without cell necrosis, degeneration, structural abnormal cells, inflammatory infiltration, etc. The HE staining results of heart and spleen tissues also showed that the staining results between the model OVX group and each drug group were similar to those of the SHAM group. These results show that after 8 weeks of intervention with LAU, hAMSCs alone or the combination of the two, no toxicity was shown on the main organs of mice.

[0049] (3) Effects of LAU and hAMSCs intervention on femoral bone mass and bone microstructure in osteoporotic mice

[0050] In order to observe the osteoporosis of mice, Micro-CT was used to analyze the changes in femoral bone mass. Figure 4 As shown in A, compared with the SHAM group, the bone mass in the OVX group was significantly reduced, and the degree of bone loss was reduced after treatment. Although the treatment effect was weaker than that of the positive drug E2 treatment group, the LAU group, hAMSCs group, and the combination group all showed significant activity in improving bone loss, and the LAU combined with hAMSCs treatment group had the least bone loss. Quantitative analysis of Micro-CT data, the results are shown in Figure 4 As shown in B and 4C, compared with the SHAM group, the BMD and Tb.N of the OVX group were significantly reduced, and recovered to varying degrees after treatment (P<0.05), but there was no significant difference in Tb.Th among the groups ( Figure 4 D). Figure 4 As shown in E and 4F, Tb.Sp in the OVX group increased significantly, while BV / TV decreased significantly, and recovered to varying degrees after treatment (P<0.05). The above results show that LAU, hAMSCs alone or their combined treatment can prevent bone loss and improve osteoporosis in OVX mice, and the hAMSCs+LAU group has better therapeutic effect than the LAU group and hAMSCs group.

[0051] Changes in cortical bone mass were also analyzed using Micro-CT. Figure 4As shown in G-4I, compared with the SHAM group, the cortical bone thickness (Ct.Th) and area (Ct.Ar) of the OVX group were significantly reduced (P<0.05), indicating that the cortical bone mass of osteoporotic mice was significantly decreased compared with that of normal mice. After treatment with the positive drug E2, Ct.Th and Ct.Ar were significantly upregulated (P<0.05), indicating that estrogen treatment can effectively improve the decrease in cortical bone mass in osteoporotic mice. However, compared with the OVX group, there was no statistical difference in Ct.Th and Ct.Ar between the LAU group, the hAMSCs group, and the combined treatment group, indicating that the use of LAU alone or in combination with hAMSCs had no significant effect on the changes in cortical bone mass in osteoporotic mice.

[0052] (4) Effects of LAU and hAMSCs intervention on serum estrogen, bone resorption and formation markers, and inflammatory factors in osteoporotic mice

[0053] In order to further evaluate the therapeutic effects of different treatment groups on osteoporotic mice, ELISA was used to detect the changes in serum estrogen, bone resorption and bone formation markers, and inflammatory factors. Figure 5 As shown in A, compared with the sham operation SHAM group, the estradiol (E2) content in the ovariectomized OVX group was significantly reduced after 8 weeks (P<0.01), indicating that the osteoporosis model in mice was successfully established; the LAU group, hAMSCs+LAU group and positive drug group were able to significantly increase the E2 level (P<0.05) after 8 weeks of treatment, but there was no statistical difference in the E2 level in the hAMSCs group alone, indicating that the use of LAU alone or in combination with hAMSCs can increase the estrogen level of osteoporotic mice, and the effect of the combination group is stronger than that of the LAU group alone.

[0054] Osteocalcin (OCN) and type I procollagen amino-terminal peptide (PINP) are indicators of bone formation, tartrate-resistant acid phosphatase (TRAP) is a marker of bone resorption and osteoclast activity, and type I collagen C-terminal peptide (CTX-I) can degrade PINP and is used to determine bone resorption. Figure 5 As shown in Figure 2, compared with the SHAM group, the serum levels of the bone formation marker OCN ( Figure 5 B) and PINP( Figure 5 C) was significantly decreased (P<0.01), and the bone resorption marker TRAP ( Figure 5 E) and CTX-I ( Figure 5 F) increased significantly (P<0.01). After treatment with LAU, hAMSCs and the combination of the two, although the effects were weaker than those of the positive control E2 group, the four bone metabolism markers all showed different degrees of improvement (P<0.01), among which the improvement effect of the hAMSCs+LAU group was better than that of the single LAU and hAMSCs treatment groups.

[0055] Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) are key signaling molecules that regulate bone absorption. Changes in their expression levels and ratios affect the formation and activation of osteoclasts. Inflammatory factors such as IL-6 are strong bone absorption stimulators. Elevated inflammatory factors can inhibit the production of OPG, leading to an increase in the RANKL / OPG ratio, accelerated osteoclast absorption and bone loss. Figure 5 D and Figure 5 G The results showed that compared with the normal group, the OPG expression in the serum of OVX group mice was decreased and the RANKL expression was increased (P<0.01), indicating that the activated osteoclasts in osteoporotic mice increased; the LAU group and hAMSCs+LAU group were able to significantly increase the OPG content and down-regulate the RANKL content (P<0.01), and although the OPG content in the hAMSCs treatment group did not change significantly, it could significantly down-regulate the RANKL content (P<0.01), indicating that the three groups can effectively inhibit the increase in bone resorption activity and reduce bone loss in osteoporotic mice, among which the hAMSCs+LAU group had the best inhibitory effect. Figure 5 H and Figure 5 The results showed that compared with the normal group, the levels of inflammatory factors TNF-α and IL-6 in the serum of OVX group mice were significantly increased (P<0.01), indicating that osteoporosis mice would be accompanied by chronic inflammation; after LAU, hAMSCs and the combined treatment of the two, the three groups could significantly reduce the levels of inflammatory factors in serum, among which the hAMSCs+LAU group had better inhibitory effect than the single LAU and hAMSCs treatment groups.

[0056] Based on the above examples, the present invention successfully constructed a PMOP model by using 8-week-old female ICR mice for bilateral ovariectomy. Through research, it was found that the use of LAU alone or in combination with hAMSCs, after continuous intervention of osteoporotic mice for 8 weeks, can improve serum estrogen levels to a certain extent, increase the levels of osteogenic markers OCN and PINP in serum, reduce the levels of osteoclast markers TRAP and CTX-I, promote the formation of trabeculae, increase bone microstructure parameters BMD, Tb.N and BV / TV, and reduce Tb.Sp, and improve PMOP by promoting bone formation and inhibiting bone resorption. Further study of its possible mechanism of action, detection of the expression levels of OPG, RANKL and inflammatory factors in serum, found that the drug intervention group can effectively regulate the expression disorder of the above cytokines, indicating that the use of LAU alone or in combination with hAMSCs can improve the inflammatory state of osteoporotic mice, by downregulating the RANKL / OPG ratio, promoting bone formation and inhibiting bone resorption to achieve bone homeostasis, showing significant anti-osteoporosis activity. The combined intervention of LAU and hAMSCs was more effective than that of LAU alone, and showed no toxicity to major organs. Therefore, the use of LAU alone or in combination with hMASCs to prepare a drug for the prevention and / or treatment of postmenopausal osteoporosis has broad market application prospects.

Claims

1. A drug, characterized in that The medicine contains norboldine.

2. The drug according to claim 1, characterized in that: The medicine also contains human amniotic mesenchymal stem cells.

3. The use according to claim 1 or 2, characterized in that: The structure of the norboldine is shown below:

4. The drug according to claim 1 or 2, characterized in that: The drug is prepared into a pharmaceutically acceptable dosage form by using norboldine as the main active ingredient and adding a pharmaceutically acceptable carrier and / or auxiliary material.

5. The drug according to claim 4, characterized in that: The dosage forms of the drug include oral dosage forms and injection dosage forms.

6. Use of the drug according to claim 1 or 2 in the preparation of a drug for preventing or treating osteoporosis.

7. The use according to claim 6, characterized in that: The osteoporosis includes specific osteoporosis, senile osteoporosis and postmenopausal osteoporosis.

8. Use of the drug according to claim 1 or 2 in the preparation of a drug for increasing trabecular bone and / or bone density.

9. Use of the drug according to claim 1 or 2 in the preparation of a drug for inhibiting bone resorption and / or promoting bone formation.